Revmedica, Inc.

The International Society for Clinical Densitometry (ISCD) is a global organization dedicated to advancing the quality of musculoskeletal health assessments and treatments for practitioners around the world. With a focus on superior patient care, ISCD provides official positions, resources, and courses to enhance the knowledge and skills of clinicians and technologists in the field of bone densitometry. Through their online courses, including the Quality Bone Densitometry Clinicians Course and the Quality Bone Densitometry Technologists Course, ISCD offers continuing education opportunities for ACCME and ASRT credit. Additionally, ISCD hosts an annual meeting, symposiums, and provides access to a knowledge base, calculators, and DXA report examples to support practitioners in their musculoskeletal health assessments. As a trusted authority in the field, ISCD is committed to promoting best practices and ensuring the highest standards in bone densitometry.Generated from the website

Lumeda Inc, based in Rocky Hill, CT, is pioneering advancements in photodynamic therapy (PDT) to enhance treatment outcomes and extend survival for patients with advanced lung and colorectal cancer. The company focuses on developing innovative medical device technology that expands the application of PDT, addressing significant treatment gaps in standard care. With its DigiLum technology, Lumeda offers a revolutionary method for administering PDT, significantly reducing treatment time while ensuring targeted effects with minimal damage to healthy tissue. The company's mission is to provide a toxicity-free alternative to traditional chemotherapy and radiotherapy, ultimately improving the quality of life for patients and enhancing the overall treatment experience. Generated from the website

BioXcel Therapeutics, Inc, situated in New Haven, CT, is at the forefront of innovation in the pharmaceutical industry. Utilizing an AI-based approach, the company focuses on re-innovating drug development to enhance research and development efficiencies. This cutting-edge methodology not only enables BioXcel Therapeutics to shorten development timelines but also significantly increases the probability of success in bringing novel treatments to market. Through their dedication to AI-driven drug re-innovation, the company strives to revolutionize patient care and improve healthcare outcomes. Generated from the website content